Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29142225 | 0.98 | IDO1 (0.41) | IDO1MAOBKCNH2KDM1AKDM1B | |
| SCHEMBL16838136 | 0.82 | IDO1 (0.42) | IDO1KCNH2KIF11CA12CA1 | |
| Hydrochloric Acid SCHEMBL27783419 | 0.80 | IDO1 (0.41) | IDO1KCNH2KIF11CA12CA1 | |
| SCHEMBL24670576 | 0.79 | IDO1 (0.40) | IDO1MAOBKCNH2KDM1AKDM1B | |
| SCHEMBL31099069 | 0.78 | RAPGEF4 (0.50) | IDO1KCNH2KIF11MAPTMEN1 | |
| SCHEMBL1421215 | 0.78 | RAPGEF4 (0.50) | IDO1KCNH2KIF11MAPTMEN1 | |
| SCHEMBL29661835 | 0.78 | CA12 (0.38) | KIF11MAPTMEN1KMT2ANPC1 | |
| SCHEMBL11742333 | 0.78 | CA12 (0.38) | KIF11MAPTMEN1KMT2ANPC1 | |
| SCHEMBL1874984 | 0.77 | KDM1A (0.41) | IDO1MAOBKCNH2KDM1AKDM1B | |
| SCHEMBL17048313 | 0.77 | IDO1 (0.42) | IDO1MAOBKCNH2KDM1AKDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| CN-118488950-A | ENPP1 inhibitors | 上海齐鲁制药研究中心有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-114634512-B | Compounds as inhibitors of bruton's tyrosine kinase, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-116635028-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-3414252-B1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH INC (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114634512-A | Compound as Bruton's tyrosine kinase inhibitor, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-113574056-A | Isoquinoline compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-112601584-A | Isoquinoline compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2021-04-02 | — | — | CN | disclosed |
| EP-2870143-B1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-8846669-B2 | Oxazolidinone derivative and medical composition containing same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-09-30 | — | — | US | disclosed |
| US-20140179691-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-06-26 | — | — | US | disclosed |
| CN-102414168-B | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD | 2014-05-21 | — | — | CN | disclosed |
| CN-102414168-A | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD | 2012-04-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179691-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | OXA1L, PAM, ABCC1 | IDO1 1648/4885MAOB 2328/4885KCNH2 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.